Clinical trial
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
NCT06353997
Study timeline
Study start (actual)2024-09-05Date precision: day
Registry last updated2026-09-16
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Triple Negative Breast Cancerunresolved
Interventions
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
INBRX-106DRUG
Sponsors & collaborators
Providence Health & Serviceslead sponsor
Inhibrx Biosciences, Inccollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06353997 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.